Novartis Ag (NVS) Free Cash Flow (QoQ) (2009 - 2026)
Powered by 
Analysis
Novartis Ag (NVS) Free Cash Flow (QoQ) (2009 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 54.23% |
| Mar 31, 2026 | -63.16% |
| Dec 31, 2025 | 57.66% |
| Sep 30, 2025 | -1.00% |
| Jun 30, 2025 | 79.40% |
| Mar 31, 2025 | -49.35% |
| Dec 31, 2024 | 16.51% |
| Sep 30, 2024 | 28.67% |
| Jun 30, 2024 | 106.06% |
| Mar 31, 2024 | -79.37% |
| Dec 31, 2023 | 114.20% |
| Sep 30, 2023 | 48.36% |
| Jun 30, 2023 | 21.63% |
| Mar 31, 2023 | -67.37% |
| Dec 31, 2022 | 93.79% |
| Sep 30, 2022 | 23.18% |
| Jun 30, 2022 | 110.49% |
| Mar 31, 2022 | -56.12% |
| Dec 31, 2021 | -17.66% |
| Sep 30, 2021 | 17.72% |